HCV NS5B polymerase inhibitors (Vertex Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameHCV NS5B polymerase inhibitors (Vertex Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVertex Pharmaceuticals Gmbh
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A